<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ru">
	<id>https://transhumanist.ru/index.php?action=history&amp;feed=atom&amp;title=IL13</id>
	<title>IL13 - История изменений</title>
	<link rel="self" type="application/atom+xml" href="https://transhumanist.ru/index.php?action=history&amp;feed=atom&amp;title=IL13"/>
	<link rel="alternate" type="text/html" href="https://transhumanist.ru/index.php?title=IL13&amp;action=history"/>
	<updated>2026-06-11T08:51:46Z</updated>
	<subtitle>История изменений этой страницы в вики</subtitle>
	<generator>MediaWiki 1.43.6</generator>
	<entry>
		<id>https://transhumanist.ru/index.php?title=IL13&amp;diff=3964&amp;oldid=prev</id>
		<title>OdysseusBot: Новая страница: «Interleukin-13 precursor (IL-13) [NC30]  ==Publications==  {{medline-entry |title=A three-dimensional dementia model reveals spontaneous cell cycle re-entry and a...»</title>
		<link rel="alternate" type="text/html" href="https://transhumanist.ru/index.php?title=IL13&amp;diff=3964&amp;oldid=prev"/>
		<updated>2021-04-29T18:53:58Z</updated>

		<summary type="html">&lt;p&gt;Новая страница: «Interleukin-13 precursor (IL-13) [NC30]  ==Publications==  {{medline-entry |title=A three-dimensional dementia model reveals spontaneous cell cycle re-entry and a...»&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Новая страница&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Interleukin-13 precursor (IL-13) [NC30]&lt;br /&gt;
&lt;br /&gt;
==Publications==&lt;br /&gt;
&lt;br /&gt;
{{medline-entry&lt;br /&gt;
|title=A three-dimensional dementia model reveals spontaneous cell cycle re-entry and a senescence-associated secretory phenotype.&lt;br /&gt;
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/32184029&lt;br /&gt;
|abstract=A hexanucleotide repeat expansion on chromosome 9 open reading frame 72 (C9orf72) is associated with familial amyotrophic lateral sclerosis (ALS) and a subpopulation of patients with sporadic ALS and frontotemporal dementia. We used inducible pluripotent stem cells from neurotypic and C9orf72  (C9 ) ALS patients to derive neuronal progenitor cells. We demonstrated that C9  and neurotypic neuronal progenitor cells differentiate into neurons. The C9  neurons, however, spontaneously re-expressed cyclin D1 after 12 weeks, suggesting cell cycle re-engagement. Gene profiling revealed significant increases in senescence-associated genes in C9  neurons. Moreover, C9  neurons expressed high levels of mRNA for [[CXCL8]], a chemokine overexpressed by senescent cells, while media from C9  neurons contained significant levels of [[CXCL8]], [[CXCL1]], [[IL13]], IP10, [[CX3CL1]], and reactive oxygen species, which are components of the senescence-associated secretory phenotype. Thus, re-engagement of cell cycle-associated proteins and a senescence-associated secretory phenotype could be fundamental components of neuronal dysfunction in ALS and frontotemporal dementia.&lt;br /&gt;
|mesh-terms=* Amyotrophic Lateral Sclerosis&lt;br /&gt;
* C9orf72 Protein&lt;br /&gt;
* Cell Cycle&lt;br /&gt;
* Cells, Cultured&lt;br /&gt;
* Cellular Senescence&lt;br /&gt;
* DNA Repeat Expansion&lt;br /&gt;
* Frontotemporal Dementia&lt;br /&gt;
* Gene Expression&lt;br /&gt;
* Gene Expression Regulation, Developmental&lt;br /&gt;
* Humans&lt;br /&gt;
* Induced Pluripotent Stem Cells&lt;br /&gt;
* Interleukin-8&lt;br /&gt;
* RNA, Messenger&lt;br /&gt;
* Stem Cells&lt;br /&gt;
|keywords=* Amyotrophic lateral sclerosis&lt;br /&gt;
* Cell cycle re-entry&lt;br /&gt;
* Frontotemporal dementia&lt;br /&gt;
* Senescence&lt;br /&gt;
* Senescence-associated secretory phenotype&lt;br /&gt;
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166179&lt;br /&gt;
}}&lt;br /&gt;
{{medline-entry&lt;br /&gt;
|title=Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis.&lt;br /&gt;
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/30685456&lt;br /&gt;
|abstract=Atopic dermatitis (AD) shows differential clinical presentation in older compared with younger patients. Nevertheless, changes in the AD molecular profile with age are unknown. We sought to characterize age-related changes in the AD profile. We evaluated age-specific changes in lesional and nonlesional tissues and blood from patients with moderate-to-severe AD (n = 246) and age-matched control subjects (n = 71) using immunohistochemistry, quantitative real-time PCR, and Singulex in a cross-sectional study. Patients were analyzed by age group (18-40, 41-60, and ≥61 years). Although disease severity/SCORAD scores were similar across AD age groups (mean, approximately 60 years; P = .873), dendritic cell infiltrates (CD1b  and FcεRI , P &amp;lt; .05) decreased with age. T 2 measures (IL5, [[IL13]], [[CCL13]], [[CCL18]], and CCL26) significantly decreased with age in patients with AD, despite increasing with age in control subjects. Consistent with T 2 axis decreases, serum IgE levels and eosinophil counts negatively correlated with age in patients with AD (r = -0.24 and r = -0.23, respectively; P &amp;lt; .05). T 22-secreted [[IL22]] expression levels also decreased with age uniquely in patients with AD (P &amp;lt; .05). Expression of T 1-related (IFNG, IL12/23p40, [[STAT1]], and CXCL9; P &amp;lt; .05 for CXCL9) and T 17-related (IL17A and IL20; P &amp;lt; .05 for IL20) markers increased with age in both patients with AD and control subjects. Expression of terminal differentiation measures significantly increased in older patients with AD (loricrin [LOR] and filaggrin [FLG], P &amp;lt; .05), whereas expression of S100As (S100A8, P &amp;lt; .01) and hyperplasia markers (epidermal thickness, keratin 16, and Ki67; P &amp;lt; .05 for keratin 16) decreased. Serum trends in AD mimicked skin findings, with T 2 downregulation (CCL26; r = -0.32, P &amp;lt; .1) and T 1 upregulation (IFN-γ; r = 0.48, P &amp;lt; .01) with age. The adult AD profile varies with age. Although T 1/T 17 skewing increases in both patients with AD and control subjects, patients with AD show unique decreases in T 2/T 22 polarization and normalization of epithelial abnormalities. Thus age-specific treatment approaches might be beneficial for AD.&lt;br /&gt;
|mesh-terms=* Adolescent&lt;br /&gt;
* Adult&lt;br /&gt;
* Aged&lt;br /&gt;
* Aged, 80 and over&lt;br /&gt;
* Aging&lt;br /&gt;
* Cytokines&lt;br /&gt;
* Dermatitis, Atopic&lt;br /&gt;
* Female&lt;br /&gt;
* Gene Expression&lt;br /&gt;
* Humans&lt;br /&gt;
* Male&lt;br /&gt;
* Middle Aged&lt;br /&gt;
* Phenotype&lt;br /&gt;
* Severity of Illness Index&lt;br /&gt;
* Skin&lt;br /&gt;
* Young Adult&lt;br /&gt;
|keywords=* Atopic dermatitis&lt;br /&gt;
* T(H)1&lt;br /&gt;
* T(H)17&lt;br /&gt;
* T(H)2&lt;br /&gt;
* T(H)22&lt;br /&gt;
* aging&lt;br /&gt;
* biomarker&lt;br /&gt;
* filaggrin&lt;br /&gt;
* hyperplasia&lt;br /&gt;
* loricrin&lt;br /&gt;
* skin&lt;br /&gt;
|full-text-url=https://sci-hub.do/10.1016/j.jaci.2019.01.015&lt;br /&gt;
}}&lt;br /&gt;
{{medline-entry&lt;br /&gt;
|title=[[IL10]]-driven [[STAT3]] signalling in senescent macrophages promotes pathological eye angiogenesis.&lt;br /&gt;
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/26260587&lt;br /&gt;
|abstract=Macrophage dysfunction plays a pivotal role during neovascular proliferation in diseases of ageing including cancers, atherosclerosis and blinding eye disease. In the eye, choroidal neovascularization (CNV) causes blindness in patients with age-related macular degeneration (AMD). Here we report that increased [[IL10]], not [[IL4]] or [[IL13]], in senescent eyes activates [[STAT3]] signalling that induces the alternative activation of macrophages and vascular proliferation. Targeted inhibition of both [[IL10]] receptor-mediated signalling and [[STAT3]] activation in macrophages reverses the ageing phenotype. In addition, adoptive transfer of [[STAT3]]-deficient macrophages into eyes of old mice significantly reduces the amount of CNV. Systemic and CD163( ) eye macrophages obtained from AMD patients also demonstrate [[STAT3]] activation. Our studies demonstrate that impaired [[SOCS3]] feedback leads to permissive [[IL10]]/[[STAT3]] signalling that promotes alternative macrophage activation and pathological neovascularization. These findings have significant implications for our understanding of the pathobiology of age-associated diseases and may guide targeted immunotherapy. &lt;br /&gt;
|mesh-terms=* Aged&lt;br /&gt;
* Aged, 80 and over&lt;br /&gt;
* Aging&lt;br /&gt;
* Animals&lt;br /&gt;
* Eye&lt;br /&gt;
* Female&lt;br /&gt;
* Humans&lt;br /&gt;
* Interleukin-10&lt;br /&gt;
* Macrophages&lt;br /&gt;
* Macular Degeneration&lt;br /&gt;
* Male&lt;br /&gt;
* Mice&lt;br /&gt;
* Mice, Inbred C57BL&lt;br /&gt;
* Middle Aged&lt;br /&gt;
* Neovascularization, Pathologic&lt;br /&gt;
* Porphyrins&lt;br /&gt;
* RAW 264.7 Cells&lt;br /&gt;
* Receptors, Interleukin-10&lt;br /&gt;
* STAT3 Transcription Factor&lt;br /&gt;
* Suppressor of Cytokine Signaling 3 Protein&lt;br /&gt;
* Suppressor of Cytokine Signaling Proteins&lt;br /&gt;
&lt;br /&gt;
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918330&lt;br /&gt;
}}&lt;/div&gt;</summary>
		<author><name>OdysseusBot</name></author>
	</entry>
</feed>